Thomas Walter
Medical oncologist in Lyon who specialises in neuroendocrine tumours and led the COMPETE phase 3 trial comparing 177Lu-edotreotide with everolimus
Department of Medical Oncology, Hôpital Édouard Herriot, Lyon (at the time of the study, 2026)
Neuroendocrine tumours of the gut and pancreas grow from hormone-making cells. Many carry receptors for the hormone somatostatin on their surface, which can be used to deliver radiation straight to the tumour: a somatostatin-like molecule is linked to a radioactive atom such as lutetium-177, an approach called peptide receptor radionuclide therapy. Everolimus, an mTOR inhibitor, is a standard drug for these tumours. In WALTER2026, Thomas Walter was first author of COMPETE, a phase 3 randomised trial in 309 patients that compared 177Lu-edotreotide with everolimus. Median progression-free survival was 23.9 months with the radioligand and 14.1 months with everolimus, and serious treatment-related side effects were less common (18 percent against 40 percent). The trial was open-label, so patients and doctors knew which treatment was given. For the mTOR field, the result means an mTOR inhibitor was the comparator that a newer therapy beat in this disease.
Walter works in the Department of Medical Oncology at Hôpital Édouard Herriot in Lyon. PubMed lists more than 140 papers under this name on neuroendocrine tumours with Lyon affiliations.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2026 | H | [177Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial. WALTER2026 First author: reported the COMPETE trial, in which 177Lu-edotreotide gave longer progression-free survival than everolimus with fewer severe side effects. |
Co-authors in the Atlas 1
People with a profile here who share at least one study with Thomas Walter.
ShowHide
- Jaume Capdevila Medical oncologist specialising in neuroendocrine and endocrine tumours
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.